8-(4-chlorophenylthio)adenosine | 85352-87-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 8-(4-chlorophenylthio)adenosine
• 英文别名: Adenosine, 8-[(4-chlorophenyl)thio]-；(2R,3R,4S,5R)-2-[6-amino-8-(4-chlorophenyl)sulfanylpurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 85352-87-0
• 化学式: C₁₆H₁₆ClN₅O₄S
• 分子量: 409.853
• InChiKey: NFZMOKLQFVMWGI-SDBHATRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  165
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-氯苯硫酚 、 8-溴膘苷 在 lithium methanolate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 8-(4-chlorophenylthio)adenosine
  参考文献：
  名称：

  SAR Analysis of Adenosine Diphosphate (Hydroxymethyl)pyrrolidinediol Inhibition of Poly(ADP-ribose) Glycohydrolase

  摘要：

  Polyadenosine diphosphoribose glycohydrolase (PARG) catalyzes the intracellular hydrolysis of adenosine diphosphoribose polymers. Because structure-activity data are lacking for PARG, the specific inhibitor adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) was utilized to determine the effects of structure on inhibitor potency using PARG isolated from bovine thymus (bPARG) and recombinant bovine PARG catalytic fragment (rPARG-CF). Both enzymes were strongly inhibited by submicromolar levels of ADP-HPD, but ADP and the phosphorylated pyrrolidine displayed no activity. Utilizing ADP-HPD analogues containing 2-, N-6, or 8-adenosyl substituents or guanine instead of adenine, the importance of adenine ring recognition as well as a correlation between loss of PARG inhibition and the length and bulkiness of 8-adenosyl substituents was shown. Utilization of ADP-HPD analogues lacking one or both pyrrolidine cis-hydroxyls demonstrated their importance for inhibitor binding. Last, the similarity between naturally occurring bPARG and heterologously expressed rPARG-CF was demonstrated. Therefore, readily available rPARG-CF is suitable for use in future studies to determine the structural aspects of PARG.

  DOI：

  10.1021/jm020541u

文献信息

• AMELIORATING AGENT FOR INSULIN RESISTANCE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2123303A1

  公开（公告）日：2009-11-25

  The present invention provides an insulin sensitizer and a prophylactic/therapeutic agent for diseases involved by sugar metabolic abnormality, comprising a substance that inhibits the expression or activity of CPSF5 protein and/or a substance that inhibits the expression or activity of CPSF6 protein. Provided as the substances are (a) an antisense nucleic acid against a nucleic acid that encodes CPSF5 (or CPSF6), (b) an siRNA against an RNA that encodes CPSF5 (or CPSF6), (c) a nucleic acid capable of producing an siRNA against an RNA that encodes CPSF5 (or CPSF6), and the like. Also provided is a screening method for an insulin resistance ameliorating substance using a cell that produces CPSF5 and/or CPSF6.

  本发明提供了一种胰岛素增敏剂和一种糖代谢异常疾病的预防/治疗剂，包括一种抑制 CPSF5 蛋白表达或活性的物质和/或一种抑制 CPSF6 蛋白表达或活性的物质。作为这些物质提供的有：(a) 针对编码 CPSF5（或 CPSF6）的核酸的反义核酸；(b) 针对编码 CPSF5（或 CPSF6）的 RNA 的 siRNA；(c) 能够产生针对编码 CPSF5（或 CPSF6）的 RNA 的 siRNA 的核酸等。还提供了一种利用产生 CPSF5 和/或 CPSF6 的细胞筛选改善胰岛素抵抗物质的方法。
• Methods and compositions for treatment of bone defects with placental cell populations
  申请人：Anthrogenesis Corporation

  公开号：EP2420567A2

  公开（公告）日：2012-02-22

  Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

  本文提供了使用附着胎盘干细胞和胎盘干细胞群的方法，以及培养、增殖和扩增这些细胞的方法。本文还提供了分化胎盘干细胞的方法。本文还提供了使用胎盘干细胞配制适合给受试者服用的可植入或可注射组合物的方法。本文还进一步提供了用干细胞和包含干细胞的组合物治疗骨缺损的方法。
• Postpartum cells derived from placental tissue, and methods of making and using the same
  申请人：DePuy Synthes Products, Inc.

  公开号：US10195233B2

  公开（公告）日：2019-02-05

  Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

  本发明提供了源自产后胎盘的细胞及其分离方法。本发明进一步提供了胎盘衍生细胞的培养物和组合物。本发明的胎盘衍生细胞具有多种用途，包括但不限于研究、诊断和治疗应用。
• Adipose-derived stem cells and lattices
  申请人：University of Pittsburgh of the Commonwealth System of Higher Education

  公开号：US20020076400A1

  公开（公告）日：2002-06-20

  The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The invention also provides a method of isolating stem cells from adipose tissues. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

  本发明提供脂肪衍生干细胞和晶格。一方面，本发明提供了基本上不含脂肪细胞和红细胞的脂肪衍生干细胞和结缔组织干细胞克隆群体。本发明还提供了一种从脂肪组织中分离干细胞的方法。细胞可单独或在生物相容性组合物中使用，在体内和体外生成分化的组织和结构。此外，还可对细胞进行扩增和培养，以产生激素，并提供条件培养基，支持其他细胞群的生长和扩增。另一方面，本发明提供了一种基本不含细胞的脂质衍生晶格，其中包括来自脂肪组织的细胞外基质材料。该晶格可用作基质，以促进细胞的生长和分化，无论是体内还是体外，使其成为原生细胞，甚至成熟的组织或结构。
• Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
  申请人：Seyda Agnieszka

  公开号：US20060166361A1

  公开（公告）日：2006-07-27

  Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

  本发明提供了源自产后胎盘的细胞及其分离方法。本发明进一步提供了胎盘衍生细胞的培养物和组合物。本发明的胎盘衍生细胞具有多种用途，包括但不限于研究、诊断和治疗应用。